Anavex Life Sciences Corp.
AVXL· Nasdaq
AVXLAnavex Life Sciences Corp.
Filed May 10, 2022 · 10-Q · 40 days after period end · 0001731122-22-000851
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Net Income | -$10.44M | -$8.16M | -$7.24M | -$7.25M |
| EPS Diluted | — | -$0.12 | -$0.12 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anavex Life Sciences Corp. · CIK 1314052 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end
